New strategies in the development of thrombolytic agents (Q39605617)

13 September 2017

1 reference

title

New strategies in the development of thrombolytic agents (English)

1 reference

13 September 2017

1 reference

H R Lijnen

1

1 reference

PubMed ID

3139109

13 September 2017

D Collen

series ordinal

2

1 reference

13 September 2017

1 October 1988

1 reference

13 September 2017

1 reference

13 September 2017

57

1 reference

13 September 2017

4

1 reference

13 September 2017

147-162

1 reference

Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

13 September 2017

1 reference

https://api.crossref.org/works/10.1007%2FBF00319543

Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00319543

Angina pectoris. What will be the requirements for acute interventional procedures in Europe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00319543

Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00319543

Synergism of thrombolytic agents in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00319543

Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents

21 January 2018

1 reference

12 December 2020

Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator with a truncated single chain urokinase-type plasminogen activator

1 reference

12 December 2020

A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction

1 reference

12 December 2020

Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator

1 reference

12 December 2020

Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect

1 reference

12 December 2020

Catabolism of human tissue plasminogen activator in mice

1 reference

12 December 2020

Characterization of functional domains in human tissue-type plasminogen activator with the use of monoclonal antibodies

1 reference

12 December 2020

Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro

1 reference

12 December 2020

Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator.

1 reference

12 December 2020

Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction

1 reference

12 December 2020

Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits

1 reference

12 December 2020

The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty

1 reference

12 December 2020

Covalent molecular weight approximately 92 000 hybrid plasminogen activator derived from human plasmin amino-terminal and urokinase carboxyl-terminal domains

1 reference

12 December 2020

Characterization of a chimaeric plasminogen activator obtained by insertion of the second kringle structure of tissue-type plasminogen activator (amino acids 173 through 262) between residues Asp130 and Ser139 of urokinase-type plasminogen activator

1 reference

12 December 2020

Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction

1 reference

12 December 2020

Autonomous functions of structural domains on human tissue-type plasminogen activator

1 reference

12 December 2020

Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin

1 reference

12 December 2020

Replacing the complementarity-determining regions in a human antibody with those from a mouse

1 reference

12 December 2020

Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator

1 reference

12 December 2020

1 reference

12 December 2020

Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator

1 reference

12 December 2020

Common evolutionary origin of the fibrin-binding structures of fibronectin and tissue-type plasminogen activator

1 reference

12 December 2020

Characterization and fibrin-binding properties of different molecular forms of pro-urokinase from a monkey kidney cell culture

1 reference

12 December 2020

The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains

1 reference

12 December 2020

Binding of tissue plasminogen activator to human umbilical vein endothelial cells

1 reference

12 December 2020

Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction

1 reference

12 December 2020

Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy

1 reference

12 December 2020

Thrombolysis by a fibrin-specific antibody Fab'-urokinase conjugate

1 reference

12 December 2020

Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs

1 reference

12 December 2020

Activation of plasminogen by pro-urokinase. I. Mechanism

1 reference

12 December 2020

Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis

1 reference

12 December 2020

Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.

1 reference

12 December 2020

Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology

1 reference

12 December 2020

Tissue-type plasminogen activator binding to human endothelial cells. Evidence for two distinct binding sites

1 reference

12 December 2020

Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin

1 reference

12 December 2020

Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158

1 reference

12 December 2020

Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis

1 reference

12 December 2020

Expression in E. coli of finger-domain lacking tissue-type plasminogen activator with high fibrin affinity.

1 reference

12 December 2020

Effect of continued rt-PA administration on the residual stenosis after initially successful recanalization in acute myocardial infarction--a quantitative coronary angiography study of a randomized trial

1 reference

12 December 2020

Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator

1 reference

12 December 2020

Interaction of one-chain and two-chain tissue plasminogen activator with intact and plasmin-degraded fibrin

1 reference

12 December 2020

Functional analysis of the human tissue-type plasminogen activator protein: the light chain

1 reference

12 December 2020

Stable acyl-derivatives of tissue-type plasminogen activator

1 reference

12 December 2020

Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator

1 reference

12 December 2020

On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture

1 reference

12 December 2020

Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis

1 reference

12 December 2020

Construction and expression of hybrid plasminogen activators prepared from tissue-type plasminogen activator and urokinase-type plasminogen activator genes

1 reference

12 December 2020

Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation

1 reference

12 December 2020

Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty

1 reference

12 December 2020

Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans.

1 reference

12 December 2020

Artificial exon shuffling between tissue-type plasminogen activator (t-PA) and urokinase (u-PA): a comparative study on the fibrinolytic properties of t-PA/u-PA hybrid proteins

1 reference

12 December 2020

Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.

1 reference

12 December 2020

Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli

1 reference

12 December 2020

Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH2-terminal domains on its biochemical and biological properties

1 reference

12 December 2020

A tissue-type plasminogen activator mutant with prolonged clearance in vivo. Effect of removal of the growth factor domain

1 reference

12 December 2020

Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis

1 reference

12 December 2020

Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits

1 reference

12 December 2020

Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo

1 reference

12 December 2020

Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro

1 reference

12 December 2020

Enzymatic properties of single-chain and two-chain forms of a Lys158----Glu158 mutant of urokinase-type plasminogen activator

1 reference

12 December 2020

Variants of human tissue-type plasminogen activator. Fibrin binding, fibrinolytic, and fibrinogenolytic characterization of genetic variants lacking the fibronectin finger-like and/or the epidermal growth factor domains.

1 reference

12 December 2020

Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers

1 reference

12 December 2020

Construction and expression of a recombinant antibody-targeted plasminogen activator

1 reference

12 December 2020

On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by epsilon-amino caproic acid

1 reference

12 December 2020

A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty

1 reference

12 December 2020

Biological and thrombolytic properties of proenzyme and active forms of human urokinase--II. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys

1 reference

12 December 2020

Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction

1 reference

12 December 2020

Mutant and chimeric recombinant plasminogen activators. Production in eukaryotic cells and preliminary characterization

1 reference

12 December 2020

Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00319543

1 reference

13 September 2017

1 reference

PubMed ID

3139109